The ApoE4 genotype modifies the relationship of long-term glycemic control with cognitive functioning in elderly with type 2 diabetes

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1303-1308

  Ravona Springer, Ramit ^a   Heymann, Anthony ^b   Schmeidler, James ^c   Sano, Mary ^c   Preiss, Rachel ^d   Koifman, Keren ^a   Hoffman, Hadas ^d   Silverman, Jeremy M ^c   Beeri, Michal Schnaider ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

ApoE; Cognition; Glycemic control; HbA1c; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN E4; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGED; ALLELE; ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CROSS-SECTIONAL STUDY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; GLYCEMIC CONTROL; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEMANTIC MEMORY; WORKING MEMORY; AGING; ATTENTION; COGNITION DISORDERS; COMPLICATION; GENETICS; GLUCOSE BLOOD LEVEL; MEMORY; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; RECOGNITION;

AGED; AGING; APOLIPOPROTEIN E4; ATTENTION; BLOOD GLUCOSE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RECOGNITION (PSYCHOLOGY);

EID: 84905020513     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.05.001     Document Type: Article

References (23)

1. Bangen K.J., Beiser A., Delano-Wood L., Nation D.A., Lamar M., Libon D.J., Bondi M.W., Seshadri S., Wolf P.A., Au R. APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis. 2013, 22(8):1361-1369.
2. Barnes L.L., Arvanitakis Z., Yu L., Kelly J., De Jager P.L., Bennett D.A. Apolipoprotein E and change in episodic memory in blacks and whites. Neuroepidemiology 2013, 40:211-219.
3. Carrion-Baralt J.R., Melendez-Cabrero J., Rodriguez-Ubinas H., Schmeidler J., Beeri M.S., Angelo G., Sano M., Silverman J.M. Impact of APOE epsilon4 on the cognitive performance of a sample of non-demented Puerto Rican nonagenarians. J. Alzheimers Dis. 2009, 18:533-540.
4. Caselli R.J., Dueck A.C., Locke D.E., Sabbagh M.N., Ahern G.L., Rapcsak S.Z., Baxter L.C., Yaari R., Woodruff B.K., Hoffman-Snyder C., Rademakers R., Findley S., Reiman E.M. Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology 2011, 76:1078-1084.
5. Dore G.A., Elias M.F., Robbins M.A., Elias P.K., Nagy Z. Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study. Diabetologia 2009, 52:2551-2560.
6. Fillenbaum G.G., Peterson B., Morris J.C. Estimating the validity of the clinical Dementia Rating Scale: the CERAD experience. Consortium to Establish a Registry for Alzheimer's Disease. Aging 1996, 8:379-385.
7. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
8. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H., Probstfield J.L., Simons-Morton D.G., Friedewald W.T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358:2545-2559.
9. Haan M.N., Shemanski L., Jagust W.J., Manolio T.A., Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. J. AM. Med. Assoc. 1999, 282:40-46.
10. Hewer W., Mussell M., Rist F., Kulzer B., Bergis K. Short-term effects of improved glycemic control on cognitive function in patients with type 2 diabetes. Gerontology 2003, 49:86-92.
11. Heymann A.D., Chodick G., Halkin H., Karasik A., Shalev V., Shemer J., Kokia E. The implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization. Diabetes Res. Clin. Pract. 2006, 71:290-298.
12. Launer L.J., Miller M.E., Williamson J.D., Lazar R.M., Gerstein H.C., Murray A.M., Sullivan M., Horowitz K.R., Ding J., Marcovina S., Lovato L.C., Lovato J., Margolis K.L., O'Connor P., Lipkin E.W., Hirsch J., Coker L., Maldjian J., Sunshine J.L., Truwit C., Davatzikos C., Bryan R.N. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011, 10:969-977.
13. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
14. Luchsinger J.A. Diabetes, related conditions, and dementia. J. Neurol. Sci. 2010, 299:35-38.
15. Meneilly G.S., Cheung E., Tessier D., Yakura C., Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J. Gerontol. 1993, 48:M117-M121.
16. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51:1256-1262.
17. Praetorius M., Thorvaldsson V., Hassing L.B., Johansson B. Substantial effects of apolipoprotein E epsilon4 on memory decline in very old age: longitudinal findings from a population-based sample. Neurobiol. Aging 2013, 34:2734-2739.
18. Ravona-Springer R., Heymann A., Schmeidler J., Guerrero-Berroa E., Sano M., Preiss R., Koifman K., Hoffman H., Levy A., Silverman J.M., Schnaider-Beeri M. Haptoglobin 1-1 genotype is associated with poorer cognitive functioning in the elderly with type 2 diabetes. Diabetes Care 2013, 36:3139-3145.
19. Ravona-Springer R., Schnaider-Beeri M. The association of diabetes and dementia and possible implications for nondiabetic populations. Expert Rev. Neurother. 2011, 11:1609-1617.
20. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 1994, 91:5710-5714.
21. Sugawara A., Kawai K., Motohashi S., Saito K., Kodama S., Yachi Y., Hirasawa R., Shimano H., Yamazaki K., Sone H. HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia 2012, 55:2128-2131.
22. Weinstein G., Beiser A.S., Decarli C., Au R., Wolf P.A., Seshadri S. Brain imaging and cognitive predictors of stroke and Alzheimer disease in the Framingham Heart Study. Stroke 2013, 44:2787-2794.
23. Yaffe K., Falvey C., Hamilton N., Schwartz A.V., Simonsick E.M., Satterfield S., Cauley J.A., Rosano C., Launer L.J., Strotmeyer E.S., Harris T.B. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch. Neurol. 2012, 69:1170-1175.